Print
Email
Print Edition Stories
Regenerative medicine firms make business of creating skin
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
RXi Pharmaceuticals Corp. of Worcester and EyeGate Pharmaceuticals Inc. of Waltham today said they will collaborate on an effort to deliver RNAi therapeutics to the eye to treat retinal disorders.
According to RXi president and CEO Noah Beerman, pre-clinical studies of RXi’s sd-rxRNA compounds have shown effective gene silencing in the retina after intraocular injection.
Now, the collaboration with EyeGate will focus on the use of EyeGate’s iontophoresis technology — a method of drug delivery that uses a low-level electrical current — to deliver the RXi compound in preclinical models.
In July, RXi won an Advanced Technology Small Business Innovation Research (SBIR) grant in the amount of $300,000 per year for two years. The Phase 1 grant is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
In June, Eyegate launched a Phase 3 clinical trial for its drug target, called EGP-437, to treat dry eye syndrome. The drug candidate is a type of steroid, delivered using the company’s proprietary, non-invasive delivery system, known as Eyegate II.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
